2009
Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells.
- Ma H, Tochigi A, Shearer TR, Azuma M.
Department of Integrative Biosciences, Oregon Health and Science University, - J Ocul Pharmacol Ther. 2009 Oct;25(5):409-14.
Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment
- Kozai S, Wada T, Kida T, Tajika T, Sakaki H, Ohtori A.
- International Journal of Antimicrobial Agents：34,561-5,2009.
POST-MARKETING SURVEILLANCE OF ACETYLCYSTEINE ORAL SOLUTION 17.6%"SENJU®" FOR THE ANTIDOTE TO ACETAMINOPHEN OVERDOSE―Use-Resultｓ Surveillance―
- Toshihide Suenobu*1, Toshiharu Yoshioka*2, Shinichi Maruta*1, Hidemi Shimoji*1
*1 Senju Pharmaceutical Co.,Ltd., *2 Osaka General Medical Center - The Japanese Journal of Clinical Toxicology. 2006(4):383－39
POST-MARKETING SURVEILLANCE ON EFFICACY AND SAFETY OF PIMARICIN OTIC SUSPENSION (MIMIENA®)
- Toshihide Suenobu*1, Hidemi Shimoji*1, Masakatsu Sato*2
*1 Senju Pharmaceutical Co.,Ltd., *2 Sato Veterinary Clinic - Jap J Vet Dermatol. 2005(4):177－187
POST-MARKETING SURVEILLANCE OF 0.1% PRANOPROFEN OPHTHALMIC SOLUTION (TEAROSE®)
- Mitsuharu Ota*1, Takashi Noma*1, Mayumi Morisaki*2
*1 Ota Veterinary Hospital, *2 Senju Pharmaceutical Co.,Ltd. - J Vet Med. 2008(12):1001－1009
POST-MARKETING SURVEILLANCE OF BROMFENAC SODIUM (BRONUCK®) OPHTHALMIC SOLUTION―Use-Resultｓ Surveillance―
- Naoko Kitao*1, Hidemi Shimoji*1, Masahiko Fukuda*2
*1 Senju Pharmaceutical Co.,Ltd. *2 Department of Ophthalmology, Kinki University School of Medicine - Atarashii Ganka. 2005(9):1299－1308
POST-MARKETING SURVEILLANCE OF GATIFLOXACIN OPHTHALMIC SOLUTION (GATIFLO® OPHTHALMIC SOLUTION 0.3%) USE-RESULT SURVEILLANCE SPECIFIED FOR NEWBORNS
- Shinichi Maruta*1, Toshihide Suenobu*1, Ra Kin Ei*2
*1 Senju Pharmaceutical Co., Ltd., *2 Ra Eye Clinic - Atarashii Ganka. 2009(10):1429－1434
POST-MARKETING SURVEILLANCE OF GATIFLOXACIN OPHTHALMIC SOLUTION (GATIFLO® 0.3% OPHTHALMIC SOLUTION) USE-RESULT SURVEILLANCE SPECIFIED FOR NEWBORNS AND INFANTS
- Shinichi Maruta*1, Toshihide Suenobu*1, Ra Kin Ei*2
*1 Senju Pharmaceutical Co., Ltd., *2 Ra Eye Clinic - Atarashii Ganka. 2007(7):975－980
Unique action mechanism of bimatoprost, in contrast with prostaglandin F2α analogs
- Tomoyuki Wada1、Larry A Wheeler2, David F Woodward2
1 千寿製薬株式会社, 2 Allergan Inc. - Jpn J Med Pharm Sci. 2009;62:525-534.
Current Situation Regarding Prostaglandin Analogs in US
- Takahiro Ogawa
- Japanese Journal of Ocular Pharmacology Vol.23 73-75, 2009
Results of Nonclinical and Clinical Studies of TalymusR Ophthalmic Suspension 0.1% for Vernal Keratoconjunctivitis
- Michinari Wada
- Japanese Journal of Ocular Pharmacology Vol.23 7-10, 2009
new | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997
